Seres Therapeutics (MCRB) Cash & Equivalents (2014 - 2026)

Seres Therapeutics has reported Cash & Equivalents for 13 years, with the latest figure at $29.8 million in Q1 2026.

• Quarterly Cash & Equivalents fell 49.3% year-over-year to $29.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.8 million (down 49.3% YoY) and the FY2025 annual result came in at $45.8 million, up 48.62% from the prior year.
• Cash & Equivalents declined to $29.8 million in Q1 2026 per MCRB's latest filing, from $45.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $248.0 million in Q1 2022 and troughed at $29.8 million in Q1 2026.
• A 5-year average of $115.9 million and a median of $94.8 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents soared 272.49% in 2022, then slumped 75.94% in 2024.
• Over 5 years, Cash & Equivalents stood at $163.0 million in 2022, then decreased by 21.51% to $128.0 million in 2023, then slumped by 75.94% to $30.8 million in 2024, then surged by 48.62% to $45.8 million in 2025, then plunged by 34.81% to $29.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $29.8 million, $45.8 million, and $47.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.